Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 66,000
+3,600 (5.77%)
At close: Feb 4, 2026
KRX:317450 Revenue
Myung In Pharmaceutical LTD. had revenue of 72.70B KRW in the quarter ending September 30, 2025, with 10.75% growth. This brings the company's revenue in the last twelve months to 283.31B. In the year 2024, Myung In Pharmaceutical LTD. had annual revenue of 269.43B with 11.18% growth.
Revenue (ttm)
283.31B
Revenue Growth
+11.18%
P/S Ratio
3.27
Revenue / Employee
845.69M
Employees
335
Market Cap
927.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 269.43B | 27.10B | 11.18% |
| Dec 31, 2023 | 242.34B | 16.51B | 7.31% |
| Dec 31, 2022 | 225.83B | 16.58B | 7.92% |
| Dec 31, 2021 | 209.25B | 21.41B | 11.40% |
| Dec 31, 2020 | 187.84B | 6.05B | 3.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HK inno.N | 839.63B |
| NOVAREX | 385.76B |
| GREEN CROSS WellBeing | 151.06B |
| DAE HWA Pharmaceutical | 149.47B |
| Vivozon Pharmaceutical | 66.40B |
| Organoidsciences | 2.55B |
| CellBion | 2.13B |
| ImmuneOncia Therapeutics | 715.75M |